USFDA Issues Form 483 with Two Observations for Dr. Reddy's FTO-11 Facility
Dr Reddys Laboratories Ltd 路 Others (Uncategorized) 路 08 Oct 2026, 9:25 pm
USFDA Issues Form 483 with Two Observations for Dr. Reddy's FTO-11 Facility The USFDA concluded a Pre-Approval Inspection (PAI) at Dr. Reddy鈥檚 Laboratories' FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, conducted between 5th Oct'26 and 7th Oct'26. Following the audit, the regulator issued a Form 483 containing two observations. The company stated it will address the cited observations within the stipulated timeline.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 14 Nov 2026
- Intimation of Analyst meet 路 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 05 Nov 2026
- Allotment of Employee Stock options 路 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... 路 03 Nov 2026
- Transcript of Earnings call 路 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 28 Oct 2026
